Ontology highlight
ABSTRACT: Background
Biologic agents are emerging as an important treatment option for immune-mediated diseases. Injection site reactions following subcutaneous injection of biologic agents is not well described in the literature.Objective
To summarize injection site reaction data in phase 3 trials of all biologic agents.Methods
MEDLINE, Embase, and CENTRAL databases were systematically searched on February 8, 2022. Proportional meta-analysis was conducted to summarize injection site reaction prevalence for each biologic.Results
There were 158 articles included in the review. The most common types of injection site reactions were erythema (42.8%), unspecified reaction (23.3%), pain (12.4%), and pruritus (5.7%). No patients discontinued their treatment due to injection
SUBMITTER: Kim PJ
PROVIDER: S-EPMC10486173 | biostudies-literature | 2023 Jul-Aug
REPOSITORIES: biostudies-literature